Acne cystic and Roaccutane


Acne Cystic Symptoms and Causes

Polycystic ovary syndrome (PCOS) happens when a woman's ovaries or adrenal glands produce more male hormones than normal. PCOS causes cysts (fluid-filled sacs) to grow on the ovaries. Symptoms include

  • Irregular menstrual periods
  • Infertility
  • Pelvic pain
  • Excess hair growth on the face, chest, stomach, or thighs
  • Weight gain
  • Acne or oily skin
  • Patches of thickened skin

Women with PCOS are at higher risk of diabetes, metabolic syndrome, heart disease, and high blood pressure.

PCOS is more common in women who have obesity, or have a mother or sister with PCOS. To diagnose PCOS, your health care provider may do a physical exam, pelvic exam, blood tests, and an ultrasound.

There is no cure, but diet, exercise, and medicines can help control the symptoms. Birth control pills help women have normal periods, reduce male hormone levels, and clear acne. Treatments for infertility caused by PCOS may include medicines, surgery, and in vitro fertilization (IVF).

NIH: National Institute of Child Health and Human Development

Check out the latest treatments for acne cystic

acne cystic treatment research studies

Roaccutane clinical trials, surveys and public health registries

Find Drug Side Effect reports

Roaccutane Side Effects

Pregnancy (163)
Depression (104)
Completed Suicide (65)
Abortion Induced (63)
No Adverse Effect (59)
No Adverse Event (46)
Suicidal Ideation (45)
Anxiety (39)
Headache (38)
Fatigue (38)
Arthralgia (29)
Suicide Attempt (29)
Dry Skin (24)
Vomiting (22)
Asthenia (18)
Dyspnoea (17)
Dry Eye (17)
Abdominal Pain (16)
Lip Dry (15)
Depressed Mood (14)
Insomnia (14)
Malaise (13)
Epistaxis (13)
Myalgia (13)
Nausea (13)
Amnesia (12)
Back Pain (12)
Acne (12)
Alopecia (12)
Abortion Spontaneous (11)
Somnolence (11)
Vision Blurred (10)
Mood Swings (10)
Aggression (10)
Anorexia (9)
Psychotic Disorder (9)
Social Avoidant Behaviour (9)
Weight Decreased (9)
Anger (8)
Abnormal Behaviour (8)
Nephrolithiasis (8)
Diarrhoea (8)
Personality Change (8)
Pyrexia (8)
Pulmonary Embolism (8)
Hypoglycaemia (7)
Intentional Self-injury (7)
Paranoia (7)
Panic Attack (7)
Normal Newborn (7)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

60mg 4 month course on Roaccutane for Acne I'm on my last pack of roaccutane now, skin has had it's spell of bad break outs and clearing up again. I believe the acne does worsen at the beginning of a course. Hopefully all cleared by the time i fin

Hai, i had been with roouc for more than six month , because of i had break out again after i finish my treatment. so i took roouc with low dosage ...10mg alternate day... but now i hardly to breath, sometime i cough, is it also the side effect? othe

I took Roaccutane over a year ago now, I suffered from very mild side effects (though still quite cringeworthy...) which were dryness of skin, especially around the mouth area, and one nose bleed (which i think was triggered by a nasty bash on the no

Im taking roaccutane 20mg for 8 days now, but i did not experience any side effects... only i get new pimples now... what does it mean?

It caused self destructive thoughts, fantasies of suicide, totally abnormal behavour, was told by family I was acting very negitivly, end result total mental breakdown,psychotic deppression ,super dry skin resulting inti hyper keratosis on

My daughter has been on roaccutane for 1 month, and her temper has gone from 0-100 in seconds i.e. verbal and physical aggression. Is this is a common side effect, and will it alleviate in time?

Roaccutane is a drug administered for the treatment of bad skin or out breaks of acne- Lots of my friends who have had bad skin and have been on it have informed me that it largely increases their penis size, adding around 1-2 extra inches. Is

This is my 17 year old sons second dose of roaccutane and last time his side affect were severe. Could you advise me on any special diet for him or what not to eat as last time he lost so much weight and severe muscle pains as well as many more side

Bre411 says Hi everyone, I am looking for any input or stories to share. I was prescribed minocycline for my acne on the 21st of December and started taking it that day, found out on the 27th of January that I am pregnant with my first baby a

Although it did help my acne. Id rather have acne thanbthe horrible stomach problems and anxiety.

Had complete hysterectomy in 1999 and developed cystis acne. Was 34 at the time. Prescribed accutane for 9 months. Worked great with the usual side effects-dry lips. Now 11 years later, I am suffering from a severe anxiety disorder with body dimorph

<span style='color: #808080;'>&iquest;En qu&eacute; est&aacute;s pensando...?I'm a Spanish teenagerpatient of Cystic Fibrosis but I've never been very affected by the illness. In fact, I have quite normal living standards

<strong></strong>after duoloton intake i was diagonosed with fatty liver with s.g.p.t.746u/l &amp; jaundice alongwith cystic fimbrae which i had to operate out

22 year old female,regrettableuseeverymonth/2months possible association with acne and generalhormonedisbalace and the symptoms that come with this.

60mg 4 month course on Roaccutane for Acne I'm on my last pack of roaccutane now, skin has had it's spell of bad break outs and clearing up again. I believe the acne does worsen at the beginning of a course. Hopefully all cleared by the time i fin

Acne or rosacea affecting the nose 8-)


Although my asthma feels very mild while using Advair I have gained weight (7 pounds) and have been getting acne around my chin area. The first time I was on advair I experienced the same side effects.

Acne Cystic Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea
Conditions: Seborrhea;   Seborrheic Dermatitis;   Quality of Life
Interventions: Drug: oral isotretinoin;   Drug: salicylic acid and ciclopirox olamine
Outcome Measures: Sebum secretion rate;   sebum secretion rate;   Oral isotretinoin side effects;   oral isotretinoin side effects
2 Not yet recruiting RA-2 13-cis Retinoic Acid (Isotretinoin)
Conditions: Male Infertility;   Klinefelter's Syndrome;   Y-chromosome Microdeletions
Intervention: Drug: 13-cis retinoic acid
Outcome Measures: Total motile sperm;   13-cis retinoic acid serum level;   Number of Participants with Serious and Non-Serious Adverse effects associated with treatment with 13-cis retinoic acid;   13-cis retinoic acid Seminal Plasma Concentration
3 Recruiting Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: monoclonal antibody Ch14.18;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: pharmacological study
Outcome Measures: EFS;   OS;   Change in MRD;   Change in tumor biology;   Incidence of toxicities assessed using Common Terminology Criteria for Adverse Events version 4.0;   Levels of ADCC;   Average level of HACA;   Historical data for the analogous patients;   13-cis-retinoic-acid pharmacokinetic parameters;   Presence of naturally occurring anti-glycan antibodies;   Genotype of Kir/Kir-Ligand;   EFS of patients from the non-randomized portion of the trial;   OS of patients from the non-randomized portion of the trial;   Cardiac repolarization;   Genotype of FcR;   Number of courses of therapy delivered
4 Recruiting Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
Conditions: Acne Vulgaris;   Isotretinoin
Outcome Measures: Therapeutic response to isotretinoin;   Adverse reaccion to isotretinoin
5 Recruiting Lenalidomide and Monoclonal Antibody With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: lenalidomide;   Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the highest dose level tested at which 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) criteria, version 4.0;   Recommended phase II dose;   Overall survival;   Event-free survival;   Changes in the levels of T cells, NK cells, monocytes, cytokines, and chemokines;   Changes in levels of HACA (or other genotype) and tumor response;   Pharmacokinetic determinations of lenalidomide;   Changes in TLDA scores;   Overall response
6 Recruiting Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Conditions: Untreated Childhood Medulloblastoma;   Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Drug: vorinostat;   Drug: isotretinoin;   Drug: vincristine sulfate;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: thiotepa;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
Outcome Measures: Dose-limiting toxicity (DLT) of proposed vorinostat as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0;   Feasibility in terms of completing 3 courses of induction therapy;   Prognostic value of histopathological classification of pediatric medulloblastoma by single-nucleotide polymorphism (SNP) analysis and gene expression analysis;   Response rate of this approach in patients with measurable residual disease (primary site and/or metastatic sites);   Progression-free survival (PFS);   Overall survival (OS);   Predictive values of biological markers in CSF, plasma and urine in the context of a feasibility study
7 Recruiting Accountability for Cancer Care Through Undoing Racism and Equity
Conditions: Breast Cancer;   Lung Cancer
Interventions: Other: ACCURE Navigator;   Other: Usual Care by Cancer Center Care Team
Outcome Measures: Lung Cancer - Lung Resection Surgery within 4 months of diagnosis Breast Cancer - Completion of surgery, radiation if surgery is breast conserving, and adjuvant chemotherapy (when indicated) within 6 months of diagnosis;   Adherence to scheduled appointments
8 Not yet recruiting Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery
Condition: HIV-1 Infection
Intervention: Drug: Isotretinoin
Outcome Measures: Change from baseline in CD8+ T-cell activation at week 14/16;   Markers of gut microbial translocation;   Markers of systemic inflammation and coagulation;   Markers of macrophage activation (sCD163);   Peripheral CD4+ T-cell count;   Th17 and Treg frequency;   Cell-associated HIV-1 DNA and RNA;   Endogenous retinoid metabolite profiles;   Primary targeted adverse events;   Pharmacokinetics - Trough concentrations of Isotretinoin and ART
9 Recruiting Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma
Interventions: Drug: doxorubicin hydrochloride;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: in vitro-treated peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cyclophosphamide;   Drug: topotecan hydrochloride;   Drug: cisplatin;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Radiation: meta-iodobenzylguanidine (MIBG) labeled with iodine-131;   Drug: busulfan;   Drug: melphalan;   Drug: isotretinoin
Outcome Measures: Proportion of MIBG avid patients treated with meta-iodobenzylguanidine (MIBG) labeled with iodine-131;   Proportion of MIBG avid patients treated with MIBG labeled with iodine-131 and Bu/Mel chemotherapy;   Percentage of average per capita income encompassed by the total of travel + housing + lost wages;   Proportion of eligible high-risk patients accrued to the study;   Event-free survival rate;   Incidence of adverse events and SOS, assessed by Common Terminology Criteria (CTC)v.4.0 for toxicity assessment and grading
10 Unknown  Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: isotretinoin;   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Pharmacokinetics of isotretinoin;   Toxicity according to NCI CTCAE v.3;   Clinical response
11 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: 3F8 and 13-cis-retinoic acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
12 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Outcome Measures: Assess the impact of high-dose 3F8/GM-CSF on relapse-free survival;   Apply real-time quantitative RT-PCR to test the hypothesis that the minimal residual disease content of bone marrow;   Monitor safety of the high-dose antibody treatment
13 Recruiting High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide
Outcome Measures: Number of Patients with Successful Engraftment;   Number of Patients with Disease Free Survival;   Overall Survival;   Number of Patients with Treatment Related Death
14 Unknown  Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: ifosfamide;   Drug: isotretinoin;   Drug: melphalan;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Drug: vindesine;   Procedure: autologous hematopoietic stem cell transplantation;   Radiation: iobenguane I 131;   Radiation: radiation therapy
Outcome Measures: Event-free survival (EFS);   Overall survival (OS);   Impact of well established clinical and molecular risk factors on EFS and OS;   Early response, measured after 2 courses of induction chemotherapy;   Response to induction therapy, measured before autologous stem cell transplantation;   Toxicity during the first 2 courses and the last 6 courses of induction chemotherapy;   Impact of the extent of initial and best surgery on outcome and frequency of complications;   Acute and late toxicity of radiotherapy;   Correlation of MIBG activity with whole-body radiation dose;   Molecular markers (MYCN and status of chromosome 1p and 11q)
15 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Outcome Measures: Event-free survival at 3 years;   Mean number of febrile events during induction;   Response rate assessed by the International Neuroblastoma Response Criteria after 4 and 8 induction chemotherapy courses;   Event-free survival at 5 years;   Overall survival;   Toxicity;   Biological factors (i.e., MycNM amplification, 1p deletion, ploidy, 17 q+, CD44, and Trk-A);   Serum concentrations of lactic dehydrogenase, ferritin, neurone specific enolase;   Urinary catecholamines at diagnosis
16 Recruiting Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
Outcome Measures: Efficacy endpoint;   Pain-toxicity endpoint;   ADCC and activated NK cell concentrations;   Soluble IL-2 receptor and CDC;   HAMA and HACA;   Absolute lymphocyte count;   Absolute NK cell numbers;   Ch14.18/CHO concentrations;   Anti-tumour response;   Confirmation cohort
17 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
Outcome Measures: Number of participants with complete or partial response;   Failure rate for the 6 cycles of induction therapy.;   Local failure rate;   Dose limiting toxicity (DLT) or severe (grade 3 or 4) VoD;   Dose limiting toxicity (DLT)
18 Recruiting 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Outcome Measures: Assess the activity of high-dose 3F8/GM-CSF;   Apply real-time quantitative RT-PCR;   Monitor safety of the high-dose antibody treatment
19 Recruiting Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: Anti-GD2 3F8 Monoclonal Antibody;   Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor);   Drug: oral isotretinoin
Outcome Measures: relapse-free survival;   complete remission
20 Recruiting Antiacne Medications Pseudotumor Cerebri
Condition: Optic Disc Swelling
Intervention: Other: Retinal nerve fibre layer measurement
Outcome Measure: Retinal nerve fibre layer